TO · AUP.TO
Aurinia Pharmaceuticals Inc.
Programmatic access: valuation JSON for this ticker · catalog · agent briefing · agent card. Paid lookups: HTTP 402 then Payment-Authorization, or Authorization: Bearer ic_live_….
Price · as of 2026-10-09
$16.76
Market cap 0
Price history
The price history chart is shown only to users with a Pro subscription.
InvestorsCraft valuation
Fair value (AI, DCF / IC, Graham) for Aurinia Pharmaceuticals Inc. (AUP.TO) is available to Pro members and via the machine API.
- AI valuation — available
- Intrinsic / IC value — available
- Upside vs price — available
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
The valuation history chart is shown only to users with a Pro subscription.
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Historic valuation ratios are shown only to users with a Pro subscription.
Line items
Line items
Line items
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.
- CEO
- Peter Greenleaf
- Employees
- 294
- Beta
- 0.28
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice.